The variation in protein size between cancer cell lines (Fig. 3E) and tumor tissues (Fig. 5C, D) in immunoblot might be due to post-translational modifications as CERS2 protein undergoes glycosylation, and the extent of glycosylation may be different in cell lines and tumor tissue. This evidence concerns the gene CERS2 and neoplasm.